Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Management of toxic optic neuropathy via a combination of Wharton’s jelly-derived mesenchymal stem cells with electromagnetic stimulation

Fig. 5

a Visual field enlargement according to study timepoints (T0, T2) in the eye treated with combination of WJ-MSC and rEMS. Note the change in FPDI values (Table 1, patient 4: left eye). (a) Before application, FPDI 47% (b) at 4th month, FPDI 65%. b Visual field enlargement according to study timepoints (T0, T2) in the eye treated with only rEMS. Note the change in FPDI values (Table 2, patient 4: right eye). (a) Before application, FPDI 46% (b) at 4th month, FPDI 53%

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512